1.	Phase II Randomized Study of Velafermin (CG53135-05) in Preventing Oral Mucositis in Patients Receiving a Conditioning Regimen Comprising High-Dose Myeloablative Chemotherapy and/or Total-Body Irradiation Followed By Autologous Hematopoietic Stem Cell Transplantation Phase: Phase II Type: Supportive care, Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: FHCRC-1972.00, CURA-C-421, NCT00124592
2.	A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CG53135-CLN-12, NCT00323518
3.	Safety and Efficacy of CG53135-05 in the Prevention of Oral Mucositis in Patients Receiving Bone Marrow Transplant Phase: Phase II Type: Supportive care, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C-421, NCT00104065